Researchers Identified New Molecule for ALS Treatment
A study has revealed that the small molecule SCC944 may help modulate protein complexes associated with neurodegenerative diseases.
Updated on Oct. 3, 2026 in Alzheimer’s
Scientists have identified SCC944 as a novel modulator of the ARF1-CSW protein complex. This discovery offers a new potential therapeutic approach for treating ALS and frontotemporal dementia (FTD).
Why it matters
Dysregulation of ARF1-GAP activity is deeply implicated in the pathogenesis of ALS and FTD. By targeting this mechanism, researchers hope to address the underlying cellular disruptions found in patients.
Researchers identified tyrosine phosphorylation at amino acid position 782 as a key marker in disease progression. The molecule identified in the study is designated as MCULE identifier 5,095,997,944.
The players
SCC944
This small molecule was identified through high-throughput in-silico screening as a modulator for the ARF1-CSW protein complex.
The details
The team utilized computer-aided drug design to isolate SCC944, which binds directly to ARF1 to reduce GTP-bound levels. This action modifies the organization of mitochondria, microtubules, and the Golgi apparatus within affected cells.
Timeline
October 3, 2026: The research findings were formally published.
The Big Picture
This study builds upon the genetic foundation provided by the C9orf72 gene hexanucleotide repeat expansion, which is a known cause of both ALS and FTD. The discovery of SCC944 bridges the gap between basic genetic research and potential pharmacological intervention.
While this discovery is a significant scientific step, it does not currently change treatment options for patients living with ALS or FTD. Future research will be required to translate these laboratory findings into viable clinical therapies.
The takeaway
Scientific advances targeting specific protein complexes provide a roadmap for developing precision medicines for neurodegenerative diseases. Patients should monitor clinical trial registries for future updates on potential therapies derived from this research.
Further reading
Learn more about the latest research in the field by visiting our Alzheimer’s section.
Source note: This article includes information reported by Nature.
